Enveric Biosciences (ENVB) Other financing activities (2015 - 2026)
Enveric Biosciences (ENVB) posted Other financing activities of $1.2 million for Q1 2026, up 165.51% sequentially from $453774.0 in Q4 2025, and up 1505.45% YoY from $75044.0 in Q1 2025.
Enveric Biosciences (ENVB) Other financing activities (2015 - 2026) Analysis & Trends
Enveric Biosciences has reported Other financing activities for 8 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Other financing activities rose 1505.45% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 7666.1% YoY) and the FY2025 annual result came in at $4.7 million, up 75.51% from the prior year.
- Other financing activities rose to $1.2 million in Q1 2026 per ENVB's latest filing, from $453774.0 in the prior quarter.
- Over five years, Other financing activities peaked at $9.4 million in Q1 2022 and troughed at -$16.3 million in Q4 2022.
- A 4-year average of $1.2 million and a median of $1.9 million in 2024 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 1506.66% in 2022, down 232343842.86% in 2022.
- Over 4 years, Other financing activities stood at -$16.3 million in 2022, then jumped by 116.46% to $2.7 million in 2024, then plunged by 83.05% to $453774.0 in 2025, then soared by 165.51% to $1.2 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $1.2 million, $453774.0, and $4.2 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Mn |
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 453,774.00 |
| Dec 31, 2025 | 453,774.00 |
| Jun 30, 2025 | 4.17 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Mar 31, 2025 | 75,044.00 |
| Mar 31, 2025 | 75,044.00 |
| Mar 31, 2024 | 2.68 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2022 | -16.26 Mn |
| Dec 31, 2022 | -16.26 Mn |
| Sep 30, 2022 | 7.82 Mn |
| Sep 30, 2022 | 7.82 Mn |
| Mar 31, 2022 | 9.40 Mn |
| Mar 31, 2022 | 9.40 Mn |
| Dec 31, 2021 | 7.00 |
| Dec 31, 2021 | 7.00 |
| Sep 30, 2021 | 486,986.00 |
| Sep 30, 2021 | 486,986.00 |